MindWalk Share Price Today

MindWalk Holdings Corp. announces CBO departure, commercial plans unchanged

Thomas Lynch, PhD, departed as Chief Business Officer effective October 16, 2026. CEO Jennifer Bath confirmed commercial priorities and contracted deployments remain unchanged. Commercial and business development teams now report directly to the CEO. LensAI™ remains in contracted, recurring arrangements with life sciences customers.

MindWalk screens 890k antibodies in under 5 hours using AMD chips

MindWalk screened 890,634 antibody sequences in 4 hours 41 minutes on AMD EPYC processors. Performance improved 37% and costs dropped 43% per sequence vs Intel Xeon instances. LensAI classified 91% of 217 tested therapeutic antibodies as having >30% immune risk. AMD Data Center revenue rose 107% YoY to $6.7 billion in Q2 2026.

MindWalk Holdings hires ex-Pfizer and Novartis leaders for preclinical push

MindWalk Holdings appointed three senior leaders from Pfizer, Novartis, and Arbor Biotechnologies. New hires focus on preclinical development, antigen discovery, and pipeline oversight. Industry trend shows AI biotechs prioritizing wet-lab validation over pure computational design. Large pharma players like Sanofi and Eli Lilly are investing heavily in validated AI-designed biologics.

MindWalk appoints Kim Remizowski as independent director

MindWalk Holdings Corp. appointed Kim Remizowski as an independent director effective September 29, 2026. Remizowski brings 35 years of institutional banking experience and serves on the Audit Committee. The Board now comprises four directors, with three classified as independent (75% ratio). AI drug discovery market forecasts vary widely, ranging from $13.8 billion by 2033 to $160.49 billion by 2035.

MindWalk cuts OpenFold3 inference time 5x with AMD, Vultr deployment

MindWalk deployed OpenFold3 on AMD Instinct MI325X GPUs via Vultr Kubernetes Engine. Antibody-antigen inference ran approximately 5x faster than in the prior environment. Production-grade prediction environment deployed in minutes using real workloads. Validation supports scaling ReefIQ adoption with standardized compute infrastructure.

MindWalk Q1FY27 revenue up 21% to $3.8 million; gross margin expands to 59%

MindWalk Q1FY27 revenue rose 21.3% YoY to $3.8 million, marking five consecutive quarters of growth. Gross margin expanded to 58.6% from 48.3%, while net loss widened to $6.1 million due to increased commercial spend. Company secured a $30 million unsecured revolving credit facility at 7% interest to fund ReefIQ rollout without equity dilution. 80% of commercial funnel value now structured as platform partnerships sharing asset economics with pharma clients.